Wilson HTM raises 12 mth target to $4.85.
Now assuming $11,500 patient for CF, but still $7,500 for bronch. So room fora large upgrage to assumptions pending results in that area.
6.6 percent is a massive result. Their main competitor which is already commercial is at 5.8 percent. And Bronchotol actually also improves efficacy of that drug by an additional 5 percent.
I think this stock will continue to run over the next few weeks.
Wilson HTM raises 12 mth target to $4.85. Now assuming $11,500...
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
0.002(6.90%) |
Mkt cap ! $40.00M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.1¢ | 3.0¢ | $18.68K | 618.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1150000 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 609832 | 2 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |